Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Carcinoma, Adenosquamous 1Carcinoma 1

Interventions

Cisplatin 8Radiotherapy 5Paclitaxel 5Docetaxel 5Cetuximab 4Carboplatin 4pembrolizumab 3figitumumab 2cemiplimab 2advexin 2Radiation 2Methotrexate 2Fluorouracil 2Drug Therapy 2Bleomycin 2vandetanib 1talimogene laherparepvec 1sintilimab 1nedaplatin 1nanocis 1methyl 5-aminolevulinate 1ficlatuzumab 1dusquetide 1brigatinib 1avasopasem manganese 1alpha-2'-deoxythioguanosine 1Vinorelbine 1Tretinoin 1Tirapazamine 1Technetium-99 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Squamous Cell × figitumumab × Clear all
NCT00596830 2014-01-13

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Pfizer

Phase 3 Terminated
681 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell

NCT00673049 2013-07-24

NSCLC

Pfizer

Phase 3 Terminated
583 enrolled 11 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡